Dyne Therapeutics (NASDAQ:DYN) Reaches New 12-Month Low – Time to Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN) shares reached a new 52-week low during trading on Tuesday . The stock traded as low as $9.96 and last traded at $10.46, with a volume of 2930532 shares traded. The stock had previously closed at $11.45.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on DYN. Guggenheim restated a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Raymond James upgraded Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Scotiabank assumed coverage on shares of Dyne Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price objective on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $45.00 target price on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Finally, Baird R W upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. One analyst has rated the stock with a sell rating, one has given a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $47.46.

Dyne Therapeutics Trading Up 7.4 %

The firm has a market cap of $1.12 billion, a P/E ratio of -2.78 and a beta of 1.11. The business has a 50-day moving average price of $13.01 and a 200-day moving average price of $22.96.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.04. On average, equities analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Activity at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the sale, the insider now owns 199,087 shares of the company’s stock, valued at $2,777,263.65. This trade represents a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 6,237 shares of company stock valued at $77,760 over the last ninety days. 20.77% of the stock is owned by company insiders.

Institutional Trading of Dyne Therapeutics

A number of institutional investors have recently modified their holdings of DYN. Janus Henderson Group PLC raised its stake in shares of Dyne Therapeutics by 8.3% during the 4th quarter. Janus Henderson Group PLC now owns 7,379,309 shares of the company’s stock worth $173,808,000 after acquiring an additional 566,146 shares in the last quarter. RTW Investments LP increased its position in shares of Dyne Therapeutics by 6.8% during the third quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock worth $244,926,000 after purchasing an additional 431,503 shares in the last quarter. RA Capital Management L.P. lifted its holdings in shares of Dyne Therapeutics by 5.5% during the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after purchasing an additional 331,940 shares during the last quarter. State Street Corp boosted its position in shares of Dyne Therapeutics by 13.8% in the 3rd quarter. State Street Corp now owns 3,641,859 shares of the company’s stock worth $130,816,000 after purchasing an additional 440,890 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Dyne Therapeutics by 1.5% during the 4th quarter. Geode Capital Management LLC now owns 1,887,329 shares of the company’s stock worth $44,476,000 after buying an additional 27,916 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.